Genmab CEO considers new acquisitions
Genmab has already made a number of acquisitions this year, but more could be on the way. The question is how much of its DKK 3 billion capital base the company is willing to spend on M&A.
BY BENJAMIN WERNER CHRISTENSEN
There is plenty of money and Jan van de Winkel is ready to spend it if the right opportunity comes along, the Dutch native, who is in charge of biotech group Genmab tells MedWatch following the publication of the company’s Q2 report.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Genmab hope could hit the market this year
For abonnenter
Genmab buys antibodies from BMS
For abonnenter
Genmab strikes deal with German biotech company
For abonnenter
